Press Release


Temple University Hospital Earns National Re-Accreditation From the American College of Surgeons Commission on Cancer

Key Takeaways

  • Temple University Hospital received re-accreditation from the ACS Commission on Cancer, confirming its high standards in cancer care.
  • CoC accreditation involves a rigorous evaluation every three years, ensuring compliance with comprehensive cancer care standards.
Abhinav Rastogi, MBA, MIS

Abhinav Rastogi, MBA, MIS

Temple University Hospital has received re-accreditation under the American College of Surgeons (ACS) Commission on Cancer (CoC) Accreditation Program. The ACS CoC is a consortium of professional organizations dedicated to improving survival and quality of life for patients with cancer by setting and raising standards.

“Temple University Hospital is thrilled to have received re-accreditation from the American College of Surgeons Commission on Cancer,” said Abhi Rastogi, MBA, MIS, President and CEO of Temple University Hospital and Executive Vice President of Temple University Health System. “This re-accreditation puts us in the company of a host of distinguished hospitals and centers that provide patients with exceptional coordinated cancer care.”

CoC accreditation is granted to institutions committed to providing high-quality cancer care by demonstrating compliance with CoC standards. Each cancer program must undergo a rigorous evaluation and review of its performance and compliance with CoC standards. To maintain accreditation, cancer programs must undergo a site visit every three years. The CoC accreditation standards supply the structure for providing all patients with a full range of diagnostic, treatment, and supportive services either on-site or by referral, including community-based resources.

“Re-accreditation from the Commission on Cancer is a testament to the strong partnership of Temple University Hospital and Fox Chase Cancer Center. Through collaboration among our physicians, researchers, and other faculty we are able to reach new heights in caring for patients and set a shining example of what collaborative care means for the health of our community,” said Robert Uzzo, MD, MBA, FACS, President and CEO of Fox Chase Cancer Center.

As a CoC-accredited institution, Temple University Hospital also becomes an ACS Surgical Quality Partner. Being a Surgical Quality Partner indicates an institution’s dedication to consistently improving procedures and approaches while maintaining a critical eye on process at every step.

The Surgical Quality Partner designation lets patients know Temple University Hospital is dedicated to quality and relentless self-improvement and has been verified or accredited by the ACS. Patients can trust that the care they receive at Surgical Quality Partner hospitals adheres to the most rigorous standards in surgical quality.

“With this re-accreditation, our patients can be assured that they are not only receiving the quality care that has become a hallmark of Temple University Hospital, but that this treatment will be provided across the cancer care continuum,” said Sukhmani Padda, MD, Vice Chair of Medical Oncology for Fox Chase at Temple University Hospital. “We are honored to be counted among our peers as a hospital that provides care of the highest caliber.”

“ACS Quality programs are grounded in more than a century of experience, and participation is an important measure of a hospital’s surgical quality,” said ACS Executive Director and Chief Executive Officer Patricia L. Turner, MD, MBA, FACS. “As an ACS Surgical Quality Partner, Temple University Hospital has shown a commitment to providing the best possible patient care, evaluating that care in a rigorous fashion, and dedicating themselves to continuous self-improvement.”

Related Videos
Robert Wang, MD, of Fox Chase Cancer Center
Alexander Kutikov, MD, FACS, of Fox Chase Cancer Center
Elizabeth Plimack, MD, MS, FASCO, an expert on bladder cancer
Efrat Dotan, MD
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer